Labiotech.eu

uk biohackathon cambridge cutec 2016 biohacking alpha brick

News and Trends 4 Jul 2016

What kind of Startups were born at the UK’s First Biohackathon?

Organised by the University of Cambridge Technology and Enterprise Club (a catchy ‘CUTEC’ for short), the Biohackathon was the first of its kind organised in the UK… With SynBio veterans such as Bento Bio (inventors of the ‘Lunch box sized Laboratory’ for hackers, schools and DIY enthusiasts), Synthace (which invented Antha – ‘the programming language of […]

July 4, 2016 - 5 minutesmins - By Dani Bancroft

abivax ceo ehrlich interview hiv hepatitis

News and Trends 4 Jul 2016

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut […]

July 4, 2016 - 5 minutesmins - By Denise Neves Gameiro

kathy high bioart biomedical research blood rats

News and Trends 2 Jul 2016

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

Kathy High is an American artist exploring the areas of technology, science, speculative fiction and art. She does this with installations and workshops – including one where the audience’s blood fights each other. Kathy High studied fine arts, English literature, video and photography at New York. On top of having a lot of well-known work in […]

July 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Jul 2016

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

The GMO debate is back into mainstream news, as 110 Nobel laureates (out of the 297 living) signed a ‘cease and desist’ open letter to Greenpeace. The target is its anti-GMO campaign, which they deem anti-scientific. And Golden Rice is the spearhead of the accusations… How many poor people in the world must die before […]

July 1, 2016 - 5 minutesmins - By Denise Neves Gameiro

bristol myers squibb immunooncology cancer opdivo psioxus

News and Trends 1 Jul 2016

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster drug with an Oncolytic viral therapy in late-stage cancer patients. Together they will evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ Enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Opdivo blockbuster (nivolumab), which […]

July 1, 2016 - 3 minutesmins - By Dani Bancroft

biotech discuva cambridge drug discovery brexit header

News and Trends 1 Jul 2016

Drug-resistant Bacteria should fear Discuva’s antimicrobials

Duty calls on the Island of Queen Elizabeth II…. What will be the future of Biotech in the United Kingdom and in Europe? Last week we did a review to catch up with all the details of #Brexit and this is why we decided to head up to Cambridge, one of the major biotech and research centers in the […]

July 1, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 30 Jun 2016

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Medigene will make its clinical debut in TCR, in a collaboration with the Max Delbrück Centre and the Charité Hospital in Berlin. The planned Phase I trial focus on the blood cancer multiple myeloma. Based near Munich (Germany), Medigene develops different anti-cancer cell therapies, as we recently discussed in an interview with former CFO […]

June 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

nash evotec biotech accellerate ellersbrook pharma liver steatohepatitis

News and Trends 30 Jun 2016

Germany joins the Biotech Front against a ‘Silent Epidemic’ of the Liver

The German life sciences investor, Ellersbrook, is putting millions into Evotec‘s drug discovery program. Together the two join a biotech industry hunt for a therapy against a metabolic liver disease (NASH) that affects 30% of adults worldwide. Ellersbrook is a life science focused investment firm owned by Herbert Stadler, a renowned biotech entrepreneur. It is now looking to accelerate […]

June 30, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Jun 2016

11 Hot Companies to Meet this Year at BioSpain

Spain has a lot of great stuff – paella, tapas, siesta! But how is Spanish biotech doing? With BioSpain 2016 approaching, we took a look at some of the most important biotechs operating in Spain and attending the event. Bonus: here is a promotional code to have a discount of 10% on your ticket BIO2016 As one […]

June 30, 2016 - 5 minutesmins - By Denise Neves Gameiro

affiris peptide vaccine affitope cholesterol

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development. Based at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. […]

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

celyad c cure chart1 ischemic heart failure

News and Trends 29 Jun 2016

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

Celyad failed to get significant results in its Phase III trial in cardiac disease. However, this cell therapy could still have a positive effect in a part of the patients. True potential or public relations patch? Cardiovascular diseases are the leading cause of death worldwide. Biotech solutions in the field range from gene therapy (with uniQure and […]

June 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 29 Jun 2016

How to Survive the Valley of Death as a Biotech Startup?

Over the past decade there has been an unprecedented restructuring of R&D in pharma whereas building a successful biotech company is still as challenging. How can these two elements help each other? This is a contributing post from Peter Machin, former SVP Drug Discovery at GSK. Big Pharma has significantly contracted its in-house […]

June 29, 2016 - 5 minutesmins - By External Contributor

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

What kind of Startups were born at the UK’s First Biohackathon?

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Blood Wars and Celebrating the Unsung Rats of Science with #BioArt

37% of all Living Nobel Laureates urged Greenpeace to stop anti-GMO campaigns

BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech

Drug-resistant Bacteria should fear Discuva’s antimicrobials

Key German Hospital to start a Phase I trial in TCR Cell Therapy

Germany joins the Biotech Front against a ‘Silent Epidemic’ of the Liver

11 Hot Companies to Meet this Year at BioSpain

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

Cell Therapy for Heart Failure fails in Phase III … but not Entirely

How to Survive the Valley of Death as a Biotech Startup?

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!